Cargando…

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

BACKGROUND: Metformin is one of the biguanides commonly used in patients with type II Diabetes Mellitus. Apart from its hypoglycemic properties, metformin also inhibits the cell cycle by restricting protein synthesis and cell proliferation via regulating the LKB1/AMPL pathway. Furthermore, it also e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Afzal, Muhammad Zubair, Mercado, Rima R., Shirai, Keisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027578/ https://www.ncbi.nlm.nih.gov/pubmed/29966520 http://dx.doi.org/10.1186/s40425-018-0375-1

Ejemplares similares

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Does denosumab offer survival benefits? —Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors
por: Cao, Yenong, et al.
Publicado: (2021)

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials
por: Yun, Seongseok, et al.
Publicado: (2016)

Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma
por: Jaberg-Bentele, Nicoletta F., et al.
Publicado: (2017)

Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report
por: Yano, Mitsutake, et al.
Publicado: (2018)

Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors
por: Afzal, Muhammad Z, et al.
Publicado: (2019)

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
por: Bowyer, S, et al.
Publicado: (2016)

Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report
por: Sone, Kenbun, et al.
Publicado: (2022)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
por: Gu, Lihu, et al.
Publicado: (2019)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
por: Puri, Sonam, et al.
Publicado: (2020)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
por: Bowyer, Samantha, et al.
Publicado: (2017)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
por: Werner, Jan-Michael, et al.
Publicado: (2019)

Anti-PD-1/PD-L1 and anti-CTLA-4 associated checkpoint inhibitor pneumonitis in non-small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
por: Hu, Xiao, et al.
Publicado: (2023)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
por: Jensen, Christina, et al.
Publicado: (2018)

Oligometastatic Melanoma Treated by Metastasectomy in Combination with Immune Checkpoint and BRAF Inhibitors: A Case Series
por: Palmer, John P., et al.
Publicado: (2023)

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
por: Wei, Spencer C., et al.
Publicado: (2019)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report
por: Cheng, An-Che, et al.
Publicado: (2021)

High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma
por: Burkard, Markus, et al.
Publicado: (2023)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study
por: Zhao, Xiaoqin, et al.
Publicado: (2018)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Jin, Ting, et al.
Publicado: (2020)

Thyroid Immune-Related Adverse Events Among Cancer Patients Treated With Combination of Anti-PD1 and Anti-CTLA4 Immune-Checkpoint Inhibitors: Clinical Course and Outcomes
por: Lui, David T W, et al.
Publicado: (2021)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma
por: Xiao, Wenjing, et al.
Publicado: (2018)

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
por: Wu, Xinqi, et al.
Publicado: (2018)

Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
por: Yu, Jui-Ling, et al.
Publicado: (2023)

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
por: Wagner, Nikolaus B, et al.
Publicado: (2018)

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o092kg5vtc1k0oavl141urc8dg